• FirefoxUpgrade to the new Firefox »
  •  Dow Up0.15% Nasdaq Up0.36%

    Alnylam Pharmaceuticals, Inc. (ALNY)

    -NasdaqGS
    100.73 Up 1.32(1.33%) Dec 19, 4:00PM EST
    |After Hours : 100.73 Down 0.00 (0.00%) Dec 19, 5:35PM EST
    Add to Portfolio
    Income StatementGet Income Statement for:
    View: Annual Data | Quarterly DataAll numbers in thousands
    Period EndingDec 31, 2013Dec 31, 2012Dec 31, 2011
    Total Revenue 47,167   66,725   82,757  
    Cost of Revenue -   -   -  
    Gross Profit 47,167   66,725   82,757  
    Operating Expenses
    Research Development112,957  86,569  99,295  
    Selling General and Administrative27,152  44,612  38,280  
    Non Recurring -  65,000   -  
    Others -   -   -  
    Total Operating Expenses -   -   -  
    Operating Income or Loss (92,942) (129,456) (54,818)
    Income from Continuing Operations
    Total Other Income/Expenses Net1,022  17,392  674  
    Earnings Before Interest And Taxes(91,920)(116,586)(57,649)
    Interest Expense -   -   -  
    Income Before Tax(91,920)(116,586)(57,649)
    Income Tax Expense(2,695)(10,572) -  
    Minority Interest -   -   -  
    Net Income From Continuing Ops(89,225)(110,536)(61,154)
    Non-recurring Events
    Discontinued Operations -   -   -  
    Extraordinary Items -   -   -  
    Effect Of Accounting Changes -   -   -  
    Other Items -   -   -  
    Net Income (89,225) (106,014) (57,649)
    Preferred Stock And Other Adjustments -   -   -  
    Net Income Applicable To Common Shares (89,225) (106,014) (57,649)

    Sign Up for a Free Trial to EDGAR Online Premium!
    Get the critical business and financial information you need for more than 15,000 U.S. public companies.
    Sign Up Now - Learn More

    Currency in USD.